Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DICE DICE Therapeutics	$47.55	$47.31	$15.08 ▼ $47.90	$2.27B	1.03	1.03 million shs	N/A
RCKT Rocket Pharmaceuticals	$2.63 -2.6%	$5.24	$2.19 ▼ $26.98	$288.32M	0.69	2.12 million shs	3.29 million shs
RCUS Arcus Biosciences	$8.65 +0.3%	$8.76	$6.50 ▼ $18.98	$912.73M	0.83	866,577 shs	638,875 shs
SRRA Sierra Oncology	$54.99	$54.93	$14.91 ▼ $55.19	$1.34B	0.03	931,731 shs	N/A

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DICE DICE Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
RCKT Rocket Pharmaceuticals	0.00%	-7.85%	-56.94%	-69.07%	-87.99%
RCUS Arcus Biosciences	0.00%	-6.32%	-4.20%	-5.25%	-47.00%
SRRA Sierra Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DICE DICE Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	4.944 of 5 stars	4.2	4.0	0.0	4.7	2.8	5.0	1.3
RCUS Arcus Biosciences	2.3251 of 5 stars	4.5	0.0	0.0	0.0	2.5	1.7	0.0
SRRA Sierra Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DICE DICE Therapeutics	0.00	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	607.22% Upside
RCUS Arcus Biosciences	2.90	Moderate Buy	$24.13	179.06% Upside
SRRA Sierra Oncology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SRRA, RCKT, RCUS, and DICE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DICE DICE Therapeutics	$1.13M	2,008.50	N/A	N/A	$10.86 per share	4.38
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A
RCUS Arcus Biosciences	$258M	3.55	N/A	N/A	$5.30 per share	1.63
SRRA Sierra Oncology	$300K	4,476.00	N/A	N/A	$6.16 per share	8.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DICE DICE Therapeutics	-$83.89M	-$2.34	N/A	N/A	N/A	N/A	-22.01%	-20.79%	N/A
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)
SRRA Sierra Oncology	-$94.66M	-$6.77	N/A	N/A	N/A	N/A	-111.88%	-100.01%	N/A

Latest SRRA, RCKT, RCUS, and DICE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DICE DICE Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
SRRA Sierra Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DICE DICE Therapeutics	N/A	25.88	32.44
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19
RCUS Arcus Biosciences	0.09	5.37	5.37
SRRA Sierra Oncology	0.02	21.27	21.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DICE DICE Therapeutics	N/A
RCKT Rocket Pharmaceuticals	98.39%
RCUS Arcus Biosciences	92.89%
SRRA Sierra Oncology	99.30%

Insider Ownership

Company	Insider Ownership
DICE DICE Therapeutics	4.90%
RCKT Rocket Pharmaceuticals	24.76%
RCUS Arcus Biosciences	9.60%
SRRA Sierra Oncology	44.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DICE DICE Therapeutics	71	47.73 million	45.39 million	Not Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable
SRRA Sierra Oncology	109	24.42 million	13.65 million	Optionable

SRRA, RCKT, RCUS, and DICE Headlines

Recent News About These Companies

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

October 4, 2024 | pharmaphorum.com

New cancer treatment center breaks ground in Redding

September 25, 2024 | actionnewsnow.com

Implementation of a Novel Pathway to Integrate Palliative and Oncology Care for Patients With Acute Myeloid Leukemia in a Community Hospital

September 19, 2024 | ascopubs.org

New regional cancer center in Redding is called the Sierra Pacific Regional Cancer Center

August 21, 2024 | actionnewsnow.com

Sierra Space eyes IPO market as it braces for a 'profound industrial revolution' in space

April 11, 2024 | msn.com

Sierra Space, valued at $5.3 billion, eyes IPO to 'accelerate the new space economy'

April 11, 2024 | aol.com

Used 2021 GMC Sierra 2500 trucks for sale near me

April 5, 2024 | cars.com

Anemia of Inflammation

March 26, 2024 | nejm.org

Sierra Oncology Inc.

February 21, 2024 | thestreet.com

Sierra Leone Airport, Sierra Leone, Sierra Leone [ SRK / ]

February 15, 2024 | prokerala.com

2014 GMC Sierra 1500 specs & colors

February 6, 2024 | cars.com

Used 2014 GMC Sierra 1500 Denali trucks for sale near me

January 5, 2024 | cars.com

2017 GMC Sierra 1500

December 17, 2023 | motortrend.com

Safety in Radiation Oncology (SAFRON)

December 16, 2023 | iaea.org

2024 GMC Sierra 2500HD

November 24, 2023 | driving.ca

Sierra deputies believe bear mauled woman after she died

November 20, 2023 | kcra.com

Sierra Coupon for October

November 9, 2023 | time.com

Compare 6 trims on the 2021 GMC Sierra 1500

October 31, 2023 | cars.com

Clario presents a three-part webinar series on oncology trial solutions

October 31, 2023 | galvnews.com

FDA approves GSK's unique myelofibrosis treatment Ojjaara

September 18, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRA, RCKT, RCUS, and DICE Company Descriptions

DICE Therapeutics NASDAQ:DICE

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.63 -0.07 (-2.59%)

Closing price 04:00 PM Eastern

Extended Trading

$2.69 +0.06 (+2.28%)

As of 07:31 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Arcus Biosciences NYSE:RCUS

$8.64 +0.03 (+0.29%)

Closing price 03:59 PM Eastern

Extended Trading

$8.45 -0.20 (-2.26%)

As of 04:52 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Sierra Oncology NASDAQ:SRRA

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time